QL Biopharm closed a roughly $72 million (500 million CNY) Series C financing led by OrbiMed and Qiming Venture Partners to advance late‑stage programs in obesity. The capital infusion will support registrational trials and potential market preparation in China, a rapidly growing market for metabolic therapeutics. QL Biopharm’s round highlights continued global investor focus on weight‑loss pharmacology and regional late‑stage players positioning for both domestic and cross‑border opportunities. The company signaled plans to expand clinical development and regulatory engagement with the new funding. For multinational obesity drugmakers, QL’s raise signals intensified competition in China and further commercialization activity in the space.